Yousif Capital Management LLC Sells 1,077 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Yousif Capital Management LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 11,328 shares of the biopharmaceutical company’s stock after selling 1,077 shares during the period. Yousif Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $8,069,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in REGN. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $49,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REGN has been the topic of several research reports. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $716.72 on Thursday. The stock has a 50-day moving average price of $718.04 and a 200 day moving average price of $916.32. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a market capitalization of $78.76 billion, a P/E ratio of 17.74, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the business posted $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.